Global Blood and Plasma Components Market 2023-2029
The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global blood and plasma components market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors approaches.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, application, end user, and region. The global market for blood and plasma components can be segmented by product: plasma-derived products, transfusion. The plasma-derived products segment was the largest contributor to the global blood and plasma components market in 2022. Blood and plasma components market is further segmented by application: hematology, solid tumor management, others. According to the research, the hematology segment had the largest share in the global blood and plasma components market. Based on end user, the blood and plasma components market is segmented into: hospitals and specialty clinics, research institutions, diagnostics laboratories, others. The hospitals and specialty clinics segment held the largest revenue share in 2022. On the basis of region, the blood and plasma components market also can be divided into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. Globally, North America made up the largest share of the blood and plasma components market.
Market Segmentation
By product: plasma-derived products, transfusion
By application: hematology, solid tumor management, others
By end user: hospitals and specialty clinics, research institutions, diagnostics laboratories, others
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America
The report explores the recent developments and profiles of key vendors in the Global Blood and Plasma Components Market, including CSL Limited, Grifols, S.A., Takeda Pharmaceutical Company Limited, ADMA Biologics Inc., Biologics, Inc., C Pharma (Green Cross Corporation), Emergent BioSolutions, Inc., LFB S.A., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
Scope of the Report
To analyze and forecast the market size of the global blood and plasma components market.
To classify and forecast the global blood and plasma components market based on product, application, end user, region.
To identify drivers and challenges for the global blood and plasma components market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global blood and plasma components market.
To identify and analyze the profile of leading players operating in the global blood and plasma components market.
Why Choose This Report
Gain a reliable outlook of the global blood and plasma components market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience
PART 2. METHODOLOGY
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
Introduction
Drivers
Restraints
PART 5. MARKET BREAKDOWN BY PRODUCT
Plasma-derived products
Transfusion
PART 6. MARKET BREAKDOWN BY APPLICATION
Hematology
Solid tumor management
Others
PART 7. MARKET BREAKDOWN BY END USER
Hospitals and specialty clinics
Research institutions
Diagnostics laboratories
Others
PART 8. MARKET BREAKDOWN BY REGION
North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America
PART 9. KEY COMPANIES
CSL Limited
Grifols, S.A.
Takeda Pharmaceutical Company Limited
ADMA Biologics Inc.
Biologics, Inc.
C Pharma (Green Cross Corporation)
Emergent BioSolutions, Inc.
LFB S.A.
DISCLAIMER
Global Whole Exome Sequencing Market 2023
DescriptionThe Whole Exome Sequencing Market is poised for substantial growth, with a projected increase from USD 1.43 billion in 2022 to USD 3.75 billion by 2029. This growth is expected
USD 1950 View ReportGlobal Continuous Bioprocessing Market 2023
DescriptionThe global Continuous Bioprocessing Market size is anticipated to expand from USD 133.9 million in 2022 to USD 443.1 million by 2029, registering a compound annual growth rate (CAGR) of
USD 1950 View ReportGlobal Blood Typing, Grouping and Infectious Disease
Global Blood Typing, Grouping and Infectious Disease NAT Screening Market--USA, Europe, Japan, 2023-2028 Volume and Sales Segment Forecasts This unique report provides information and analysis not available from any
USD 12500 View ReportGlobal Blood Group Typing Market 2023-2029
Blood group typing is typically performed using a small blood sample, which is then sent to a laboratory for testing. Results are usually available on the same day or the
USD 2350 View ReportFill The Form For Sample Request